|
|
|
19 March 2020
Phil Kerpen, President of American Commitment, discusses how government price controls harm consumers, why price controls on consumer lending and prescription drugs must be rejected, and what to expect if the U.S. Postal Service becomes a lending station.
0:00
0:00
Related Podcasts
04 April 2025
Sally Pipes, President and CEO of Pacific Research Institute, discusses her recently released book, “The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy and How to Keep It,” the horrible impacts of price controls, how single-payer healthcare systems fail children and cancer patients, and more.
02 September 2024
Sally Pipes, Founder and President of Pacific Research Institute, discusses the impact of drug price controls under the Inflation Reduction Act (IRA), what it means for research and development of life-saving medicines, and how the IRA's drug pricing provisions will reduce access to new cures and treatments and result in longer wait times for existing medicines.
28 June 2024
Sally Pipes, President and CEO of Pacific Research Institute, discusses how President Biden's price controls will result in prescription drug shortages and discourage innovation, how government mandates and regulations raise insurance costs, and the grim prognosis on Medicare and Medicaid's viability.
01 March 2024
Sally Pipes, President and CEO at the Pacific Research Institute, discusses how President Biden's drug price controls undermine his Cancer Moonshot initiative, and the ultimate impact price controls will have on patient lives, innovation, and research and development.
13 October 2022
Sally Pipes, President and CEO of Pacific Research Institute, discusses the likely disastrous effects of drug price control provisions contained in the Inflation Reduction Act and why Congress should embrace a free-market vision when it comes to healthcare by lowering taxes, encouraging innovation and expanding access.
14 February 2020
Timothy Lee, Senior Vice President of Legal and Public Affairs at CFIF, discusses the DOJ's civil antitrust lawsuit seeking to block Sabre Corporation's acquisition of Farelogix, Inc., and why imported price controls for drugs is a prescription for failure.
